![Stephanie Tozzo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephanie Tozzo
Directeur Technique/Scientifique/R&D chez Avilar Therapeutics, Inc.
Fortune : - $ au 31/05/2024
Postes actifs de Stephanie Tozzo
Sociétés | Poste | Début | Fin |
---|---|---|---|
Avilar Therapeutics, Inc.
![]() Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Directeur Technique/Scientifique/R&D | 01/11/2021 | - |
Corporate Officer/Principal | 01/11/2021 | - |
Historique de carrière de Stephanie Tozzo
Anciens postes connus de Stephanie Tozzo
Sociétés | Poste | Début | Fin |
---|---|---|---|
COHBAR, INC. | Directeur/Membre du Conseil | 11/07/2022 | 10/11/2023 |
Formation de Stephanie Tozzo
Université Paris-Saclay | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 3 |
France | 2 |
Opérationnelle
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 2 |
Commercial Services | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
COHBAR, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Avilar Therapeutics, Inc.
![]() Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Commercial Services |
- Bourse
- Insiders
- Stephanie Tozzo
- Expérience